Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | LSS | P48449 | 2/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9517403 | 0.88 | HTR3A (0.48) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL9517400 | 0.88 | HTR3A (0.48) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL9181742 | 0.87 | HTR3A (0.44) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL9181738 | 0.87 | HTR3A (0.44) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL315186 | 0.85 | HTR3A (0.58) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL11315431 | 0.80 | SRD5A1 (0.46) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL218475 | 0.80 | HTR3A (0.59) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL435619 | 0.80 | HTR3A (0.59) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL11315434 | 0.79 | HTR3A (0.48) | HTR3ADRD2LSSSLC18A3SRD5A1 | |
| SCHEMBL127746 | 0.78 | HTR3A (0.57) | HTR3ADRD2LSSSLC18A3SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| CN-104628555-B | A kind of synthetic method of pharmaceutical intermediate 4-(4-chlorphenyl) cyclohexyl-1-formic acid | 烟台蓓丰医药科技有限公司 | 2016-11-30 | — | — | CN | claimed |
| CN-103772239-A | Novel amide and amidine derivatives and uses thereof | ABBVIE INC | 2014-05-07 | — | — | CN | claimed |
| US-8697684-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2014-04-15 | — | — | US | claimed |
| US-20130280212-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC (US) | 2013-10-24 | — | — | US | claimed |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (US) | 2013-09-12 | — | — | US | claimed |
| US-8450303-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-28 | — | — | US | claimed |
| US-8426401-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV | 2013-04-23 | — | — | US | claimed |
| US-20060178403-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-08-10 | — | — | US | claimed |
| WO-2004081005-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | claimed |
| EP-0580185-B1 | New Naphthoquinones and their use as medicaments | WELLCOME FOUND (GB) | 1999-03-31 | — | — | EP | claimed |
| EP-0634996-A1 | 1,4 NAPHTHOQUINONE DERIVTIVES WITH ANTI-PROTOZOAL AND ANTI-PARASITIC ACTIVITY | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-01-25 | — | — | EP | claimed |
| CN-1083048-A | Heterogeneous ring compound | WELLCOME FOUND (GB) | 1994-03-02 | — | — | CN | claimed |
| EP-0580185-A1 | Medicaments | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-26 | — | — | EP | claimed |
| WO-1993020044-A1 | 1,4 NAPHTHOQUINONE DERIVTIVES WITH ANTI-PROTOZOAL AND ANTI-PARASITIC ACTIVITY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-10-14 | — | — | WO | claimed |
| EP-0537947-A1 | Naphthoquinone derivatives for the treatment of parasitic infections | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-04-21 | — | — | EP | claimed |
| WO-1993007156-A1 | NAPHTHOQUINONE DERIVATIVES FOR THE TREATMENT OF PARASITIC INFECTIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-04-15 | — | — | WO | claimed |
| EP-0362996-A2 | Naphthoquinones for the treatment and prophylaxis of pneumocystis carinii infections | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130280212-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | HTR3A 2294/4885DRD2 4727/4885LSS 247/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | HTR3A 3308/4885DRD2 4611/4885LSS 1151/4885 |
| US-20130237517-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | HTR3A 2954/4885DRD2 865/4885LSS 119/4885 |
| US-20060178403-A1 | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | MCHR1, MCHR2, MC1R | HTR3A 77/4885DRD2 517/4885LSS 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.